Evidence map›Paper›PMID 39455636›Full record

ArticleScientific reports2024

Discovery of Jaspamycin from marine-derived natural product based on MTA3 to inhibit hepatocellular carcinoma progression.

Yihan Liu, Tong Lu, Runze Li, Rui Xu, Denis Baranenko, Lida Yang, Dan Xiao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yihan LiuGraduate School, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, 150001, China.
Tong LuMedical Technology Department, Qiqihar Medical University, Qiqihar, Heilongjiang, 161006, China.
Runze LiNational and Local Joint Engineering Laboratory for Synthesis Transformation and Separation of Extreme Environmental Nutrients, Harbin Institute of Technology, Harbin, Heilongjiang, 150001, China.
Rui XuCancer Hospital, Shenzhen Hospital, National Cancer Center, National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, Guangdong, China.
Denis BaranenkoSchool of Life Sciences, Faculty of Ecotechnologies, ITMO University, St. Petersburg, 197101, Russia.
Lida YangHeilongjiang Nursing Collage, Harbin, Heilongjiang, 150086, China.
Dan XiaoNational and Local Joint Engineering Laboratory for Synthesis Transformation and Separation of Extreme Environmental Nutrients, Harbin Institute of Technology, Harbin, Heilongjiang, 150001, China. xiaodan@hit.edu.cn.

Funding

Heilongjiang Province Ordinary University Youth Innovation Talent Cultivation UNPYSCT-2020159National Natural Science Foundation of China 82104173
6 · The paper itself

Abstract

Studies have underscored the pivotal role of metastasis-associated protein 3 (MTA3) as a cancer regulator, yet its potential as a drug target across cancers necessitates comprehensive evaluation. In this study, we analyzed MTA3 expression profiles to ascertain its diagnostic and prognostic value in pan-cancers, probing associations with genetic variations and immunological characteristics. Notably, liver hepatocellular carcinoma (LIHC) exhibited the most significant correlation with MTA3. By transfection of siRNA, interference of MTA3 affected HepG2 and Hepa1-6 cell viability and migration. Through drug screening and drug-likeness evaluation among marine-derived natural products, Jaspamycin was identified as a potential hepatocellular carcinoma treatment by targeting MTA3. By applying in vitro and in vivo experiment, the inhibitory effects of Jaspamycin on hepatocellular carcinoma viability, migration, and tumor progression were observed. To assess the potential of MTA3 as an anticancer drug target, MTA3 overexpression plasmid was transfected together with Jaspamycin treatment, and observed that MTA3 upregulation counteracted the inhibitory effects of Jaspamycin on hepatocarcinoma cell proliferation and migration, underscoring the efficacy of MTA3 as a drug target in hepatocellular carcinoma drug screening. This study highlights the clinical significance of MTA3 in pan-cancer, particularly in hepatocellular carcinoma. Additionally, it identifies Jaspamycin, a marine-derived compound with promising pharmacological properties, as an effective inhibitor of MTA3 activity, suggesting its potential for hepatocellular carcinoma treatment.

Indexed as

Carcinoma, HepatocellularCell MovementCell ProliferationLiver NeoplasmsAnimalsAntineoplastic AgentsAquatic OrganismsBiological ProductsCell Line, TumorCell SurvivalDisease ProgressionGene Expression Regulation, NeoplasticHep G2 CellsHumansMiceNeoplasm ProteinsAntineoplastic AgentsBiological ProductsMTA3 protein, humanNeoplasm ProteinsHepatocellular carcinomaJaspamycinMarine-derived anticancer agentMTA3Pan-cancer

Identifiers

PMID39455636
PMCPMC11511890

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.